Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/pds.5345 http://scihub22266oqcxt.onion/10.1002/pds.5345 34390285!8441753!34390285     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacoepidemiol+Drug+Saf 2021 ; 30 (11): 1486-1492 Nephropedia Template TP {{tp|p=34390285|t=2021. Association between inhaled corticosteroid use and COVID-19 outcomes |pdf=|usr=}}{{34390285}} gab.com Text Association between inhaled corticosteroid use and COVID-19 outcomes JO: Pharmacoepidemiol Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34390285 #FOAvip BACKGROUND: Recent evidence has established a beneficial effect of systemic corticosteroids for treatment of moderate-to-severe COVID-19. OBJECTIVE: To determine if inhaled corticosteroid use is associated with COVID-19 outcomes. METHODS: In a nationwide cohort of hospitalized SARS-CoV-2 test-positive individuals in Denmark, we estimated the 30-day hazard ratio of intensive care unit (ICU) admission or death among users of inhaled corticosteroids (ICS) compared with users of bronchodilators (beta(2) -agonist/muscarinic-antagonists), and non-users of ICS overall, with Cox regression adjusted for age, sex, and other confounders. We repeated these analyses among influenza test-positive patients during 2010-2018. RESULTS: Among 6267 hospitalized SARS-CoV-2 patients, 614 (9.8%) were admitted to ICU and 677 (10.8%) died within 30 days. ICS use was associated with a hazard ratio of 1.09 (95% CI [CI], 0.67 to 1.79) for ICU admission and 0.78 (95% CI, 0.56 to 1.11) for death compared with bronchodilator use. Compared with no ICS use overall, the hazard ratio of ICU admission or death was 1.17 (95% CI, 0.87-1.59) and 1.02 (95% CI, 0.78-1.32), respectively. Among 10 279 hospitalized influenza patients, of which 951 (9.2%) were admitted to ICU and 1275 (12.4%) died, the hazard ratios were 1.43 (95% CI, 0.89-2.30) and 1.11 (95% CI, 0.85-1.46) for ICU admission, and 0.80 (95% CI, 0.63-1.01) and 1.03 (95% CI, 0.87-1.22) for death compared with bronchodilator use and no ICS use overall, respectively. CONCLUSION: Our results do not support an effect of inhaled corticosteroid use on COVID-19 outcomes, however we can only rule out moderate-to-large reduced or increased risks. STUDY REGISTRATION: The study was pre-registered at encepp.eu (EUPAS35897). Twit Text FOAVip Association between inhaled corticosteroid use and COVID-19 outcomes ????Pharmacoepidemiol Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34390285 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34390285 #FOAvip English Wikipedia <ref>{{Cite pmid|34390285}}</ref> Association between inhaled corticosteroid use and COVID-19 outcomes #MMPMID34390285 Husby A; Pottegard A; Hviid A Pharmacoepidemiol Drug Saf 2021[Nov]; 30 (11): 1486-1492 PMID34390285show ga BACKGROUND: Recent evidence has established a beneficial effect of systemic corticosteroids for treatment of moderate-to-severe COVID-19. OBJECTIVE: To determine if inhaled corticosteroid use is associated with COVID-19 outcomes. METHODS: In a nationwide cohort of hospitalized SARS-CoV-2 test-positive individuals in Denmark, we estimated the 30-day hazard ratio of intensive care unit (ICU) admission or death among users of inhaled corticosteroids (ICS) compared with users of bronchodilators (beta(2) -agonist/muscarinic-antagonists), and non-users of ICS overall, with Cox regression adjusted for age, sex, and other confounders. We repeated these analyses among influenza test-positive patients during 2010-2018. RESULTS: Among 6267 hospitalized SARS-CoV-2 patients, 614 (9.8%) were admitted to ICU and 677 (10.8%) died within 30 days. ICS use was associated with a hazard ratio of 1.09 (95% CI [CI], 0.67 to 1.79) for ICU admission and 0.78 (95% CI, 0.56 to 1.11) for death compared with bronchodilator use. Compared with no ICS use overall, the hazard ratio of ICU admission or death was 1.17 (95% CI, 0.87-1.59) and 1.02 (95% CI, 0.78-1.32), respectively. Among 10 279 hospitalized influenza patients, of which 951 (9.2%) were admitted to ICU and 1275 (12.4%) died, the hazard ratios were 1.43 (95% CI, 0.89-2.30) and 1.11 (95% CI, 0.85-1.46) for ICU admission, and 0.80 (95% CI, 0.63-1.01) and 1.03 (95% CI, 0.87-1.22) for death compared with bronchodilator use and no ICS use overall, respectively. CONCLUSION: Our results do not support an effect of inhaled corticosteroid use on COVID-19 outcomes, however we can only rule out moderate-to-large reduced or increased risks. STUDY REGISTRATION: The study was pre-registered at encepp.eu (EUPAS35897). |*COVID-19[MESH] |Adrenal Cortex Hormones/adverse effects[MESH] |Hospitalization[MESH] |Humans[MESH] |Intensive Care Units[MESH]Association between inhaled corticosteroid use and COVID-19 outcomes (epmc).pdf DeepDyve Pubget Overpricing